These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9143248)

  • 1. Macrophage infiltration at the neuromuscular junction does not contribute to AChR loss and age-related resistance to EAMG.
    Hoedemaekers A; Graus Y; Beijleveld L; van Breda Vriesman P; De Baets M
    J Neuroimmunol; 1997 May; 75(1-2):147-55. PubMed ID: 9143248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related resistance to experimental autoimmune myasthenia gravis in rats.
    Graus YM; Verschuuren JJ; Spaans F; Jennekens F; van Breda Vriesman PJ; De Baets MH
    J Immunol; 1993 May; 150(9):4093-103. PubMed ID: 8386206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
    J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related susceptibility to experimental autoimmune myasthenia gravis: immunological and electrophysiological aspects.
    Hoedemaekers AC; Verschuuren JJ; Spaans F; Graus YF; Riemersma S; van Breda Vriesman PJ; De Baets MH
    Muscle Nerve; 1997 Sep; 20(9):1091-101. PubMed ID: 9270663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis.
    Hoedemaekers A; Bessereau JL; Graus Y; Guyon T; Changeux JP; Berrih-Aknin S; van Breda Vriesman P; De Baets MH
    J Neuroimmunol; 1998 Aug; 89(1-2):131-41. PubMed ID: 9726835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
    Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
    Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.
    Lindstrom JM; Einarson BL; Lennon VA; Seybold ME
    J Exp Med; 1976 Sep; 144(3):726-38. PubMed ID: 182896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis.
    De Baets MH; Verschuuren J; Daha MR; van Breda Vriesman PJ
    Immunol Res; 1988; 7(3):200-11. PubMed ID: 3264006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement associated pathogenic mechanisms in myasthenia gravis.
    Tüzün E; Christadoss P
    Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrastructural aspects of acetylcholine receptor turnover at the normal end-plate and in autoimmune myasthenia gravis.
    Fumagalli G; Engel AG; Lindstrom J
    J Neuropathol Exp Neurol; 1982 Nov; 41(6):567-79. PubMed ID: 6982313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age- and sex-related resistance to chronic experimental autoimmune myasthenia gravis (EAMG) in Brown Norway rats.
    Hoedemaekers A; Graus Y; van Breda Vriesman P; de Baets M
    Clin Exp Immunol; 1997 Jan; 107(1):189-97. PubMed ID: 9010275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in acetylcholinesterase in experimental autoimmune myasthenia gravis and in response to treatment with a specific antisense.
    Blotnick E; Hamra-Amitai Y; Wald C; Brenner T; Anglister L
    Eur J Neurosci; 2012 Oct; 36(8):3077-85. PubMed ID: 22805122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
    Meinl E; Klinkert WE; Wekerle H
    Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor.
    Engel AG; Sakakibara H; Sahashi K; Lindstrom JM; Lambert EH; Lennon VA
    Neurology; 1979 Feb; 29(2):179-88. PubMed ID: 571062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis.
    Krolick KA; Yeh TM; Edlund SA
    Cell Immunol; 1996 Aug; 172(1):10-20. PubMed ID: 8806801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.
    Bionda A; De Baets MH; Tzartos SJ; Lindstrom JM; Weigle WO; Theophilopoulos AN
    Clin Exp Immunol; 1984 Jul; 57(1):41-50. PubMed ID: 6611231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AChR-specific immunosuppressive therapy of myasthenia gravis.
    Luo J; Lindstrom J
    Biochem Pharmacol; 2015 Oct; 97(4):609-619. PubMed ID: 26215875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
    Loutrari H; Kokla A; Tzartos SJ
    Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.